Quantitative ER and PgR Assessment as Predictors of Benefit From Lapatinib in Postmenopausal Women With Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-13-1260
Full Text
Open PDFAbstract
Available in full text
Date
November 6, 2013
Authors
Publisher
American Association for Cancer Research (AACR)